Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA203 + mRNA-4203 in cutaneous melanoma and synovial sarcoma
NCT06946225Phase 1Recruiting
- Sponsor
- Immatics
- Start
- Jul 2025
- Primary completion
- Aug 2029
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRAME TCR T cells in cutaneous melanoma (CM) and synovial sarcoma (SS), sponsored by Immatics. Primary endpoints: Dose-Limiting Toxicities at 1 year and Adverse Events at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
PRAME TCR T cells
03
Conditions
cutaneous melanoma (CM)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT06946225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946225.